Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.34 |
| ▸ | WDR5 | P61964 | 4/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
| ▸ | ULK1 | O75385 | 1/20 | 0.32 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13137042 | 0.94 | ULK1 (0.35) | CCR2OPRM1OPRD1OPRK1WDR5 | |
| Trifluoroacetic Acid SCHEMBL3041959 | 0.91 | SLC2A1 (0.36) | CCR2OPRM1OPRD1OPRK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL3041840 | 0.87 | CCR2 (0.38) | CCR2OPRM1OPRD1OPRK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL1873575 | 0.86 | PTK2 (0.35) | CCR2OPRM1OPRD1OPRK1EPHX2 | |
| Trifluoroacetic Acid SCHEMBL3048634 | 0.84 | SLC2A1 (0.45) | SLC2A1HTR5A | |
| Trifluoroacetic Acid SCHEMBL3047273 | 0.83 | OPRM1 (0.36) | CCR2OPRM1OPRD1OPRK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL1878705 | 0.81 | CCR2 (0.37) | CCR2OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3049039 | 0.81 | OPRM1 (0.35) | CCR2OPRM1OPRD1OPRK1SLC2A1 | |
| Hydrochloric Acid SCHEMBL3045140 | 0.81 | QPCT (0.36) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13137048 | 0.81 | QPCT (0.37) | OPRM1OPRD1OPRK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | CCR2 369/4885OPRM1 2/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.